Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
-TRIAL DATA Phase 2 Clinical Research Results A randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluated retatrutide across multiple dose groups over a 48-week period
In other words, barely 1 in 7 patients remains on GLP-1 therapy after two years , despite obesity being a chronic condition requiring long-term treatment
Unlike semaglutide (Ozempic/Wegovy), which activates a single receptor (GLP-1), or tirzepatide (Mounjaro/Zepbound), which activates two (GLP-1 + GIP), retatrutide activates three metabolic receptors at once: GLP-1 slows gastric emptying, suppresses appetite, improves insulin response GIP additional insulin-sensitivity and appetite effects Glucagon boosts energy expenditure and lipolysis (this is the new mechanism) The glucagon component is what makes retatrutide unique
Shyangdan, D
Potential evening downsides The biggest risk with evening dosing is forgetting
US$ 20.61
US$ 27.35
US$ 23.66
US$ 29.43
